Please login to the form below

Not currently logged in
Email:
Password:

Jutta Heim joins Nuevolution

Takes role as director and scientific advisor at Danish discovery company

Nuevolution Jutta HeimNuevolution has appointed Prof Dr Jutta Heim as director and senior scientific advisor to its board of directors.

She brings to the Copenhagen-based small molecule lead discovery company more than 20 years of experiences working for Ciba-Geigy/Novartis.   

She was involved in the development and launch of anti-thrombotic and fibrinolytic products and established Novartis' oncology molecular genetics department.  

Prof Heim served as Novartis' senior scientific expert in molecular biology, was a member of its research management board and finished her time with the company heading the Novartis Lead Discovery Center with worldwide responsibility.  

She has also served as CSO at Swiss biopharma company Basilea Pharmaceutica, which focuses on anti-infectives, inflammation and oncology.  

Most recently Prof Heim was chief technology officer and chief scientific officer at health, wellness and nutrition company Evolva, 2009 to 2013.  

Alex Gouliaev, Nuevolution CEO, said: “Jutta's significant expertise and input has already been well appreciated by management and our board. We are certain that her experience from the industry, broad insight into general drug discovery and, in particular, within oncology will add significant value to the company.”

28th August 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics